Xcout Intel
SENSORION
Sensorion is a French biopharmaceutical company developing therapies for inner-ear disorders, including hearing loss and vestibular diseases. Its products are intended for patients with debilitating auditory and balance-related conditions, serving healthcare providers and the broader biopharmaceutical market.
Subscribe to see SENSORION’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
SENSORION at a glance
SENSORION is a biotech company headquartered in France. Xcout tracks 17 named people at SENSORION, including Fred Chereau (Directeur Général).
SENSORION leadership
- Fred ChereauDirecteur Général
- Laurène DanonDirectrice Financière
- Bernd SchmidtDirecteur des Opérations Techniques
- Christine Le BecDirectrice CMC Thérapie Génique
- Laurent DésiréResponsable du Développement Préclinique
- Rachel CooperDirectrice de l'Audiologie
11 more named people on record for SENSORION, with roles, board committees and tenure — see the full roster →
SENSORION competitors
A few of SENSORION's closest competitors — see the full list of competitors and alternatives →
Spiral Therapeutics Inc. is a clinical-stage pharmaceutical company based in South San Francisco, California, focused on delivering targeted therapies for inner ear conditions.
GenSight Biologics is a clinical-stage biopharmaceutical company that develops gene therapies to treat neurodegenerative retinal diseases and central nervous system disorders. The company focuses on addressing conditions such as Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa, and Geographic Atrophy using technologies like gene therapy, mitochondrial targeting sequences, and optogenetics.
Acousia Therapeutics GmbH is a privately held biotechnology company founded in 2012 to develop therapeutics fighting hearing loss. Supported by a strong investor consortium, the company is based in Tübingen, Germany.
Oricula Therapeutics LLC is a biotechnology company developing medications designed to prevent drug-induced hearing loss. Its lead product candidate, an oral medication called ORC-13661, aims to protect inner ear hair cells from the damaging side effects of aminoglycoside antibiotics.
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Corteria Pharmaceuticals is a privately held biopharmaceutical company based in Paris, France, focused on developing first-in-class drugs for indications with high unmet medical need, particularly heart failure.
Get SENSORION's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on SENSORION in Xcout Intel
- 17 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access